Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breath Analysis May Replace Blood Sampling to Monitor Drug Usage

By LabMedica International staff writers
Posted on 14 Oct 2019
A simple and non-invasive technique to collect exhaled breath condensate (EBC) from chronic pain patients was developed, and its usefulness was confirmed by comparing metabolites in breath and blood samples following use of different analgesic opioid drugs.

A breath test would be a useful alternative to blood sampling in caring for chronic pain patients as well as for checking for illegal drug use. More...
Furthermore, there is a lack of information regarding these drugs and their metabolites contained in breath, as well as their pharmacokinetics.

The intent of a study conducted by investigators at the University of California, Davis (USA) was to use pain management drugs, such as morphine and hydromorphone, as model drugs to determine breath composition, metabolite detection, and correlation with blood concentrations after controlled administration, together with other administered medications.

For the study, six patients were given continuous infusion of morphine and hydromorphone intravenously (IV), together with other analgesic drugs (IV and orally). Repeated sampling of serum and EBC was done at two time points separated by 90 minutes. The EBC was collected using a glass tube surrounded by dry ice, and an ethanol solvent wash of the glass was performed after EBC extraction to retrieve the apolar compounds stuck to the glass surface. All samples were analyzed with liquid chromatography coupled to mass spectrometry (LC-MS/MS) to identify possible metabolites present in the sample, and to quantify the drugs being used.

Results revealed that several metabolites, such as normorphine (norM), norhydromorphone (norHM), and dihydromorphone (diHM) were detected in both fractions, while hydromorphone 3-glucuronide (HM 3G) was only detected in the solvent rinse fraction. Promising correlations were found between drug concentrations in blood and breath at different time points for norM, norHM, and HM 3G.

"We can see both the original drug and metabolites in exhaled breath," said senior author Dr. Cristaina Davis, professor of mechanical and aerospace engineering at the University of California, Davis. "There are a few ways we think this could impact society."

The EBC study was published in the October 3, 2019, online edition of the Journal of Breath Research.

Related Links:
University of California, Davis


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
POC Immunoassay Analyzer
Procise DX
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.